FDA Approves Opdivo, Yervoy Combination For Kidney Cancer | Latest News RSS feed

FDA Approves Opdivo, Yervoy Combination For Kidney Cancer - Latest News

FDA Approves Immunotherapy Combination for Metastatic Colorectal Cancer

The Food and Drug Administration (FDA) approved the combination ... Opdivo (nivolumab) plus Yervoy (ipilimumab) for patients with previously treated microsatellite instability-high (MSI-H) or DNA ... read more

BMS gets new OK for Opdivo/Yervoy in kidney cancer

PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab ... rejected the drug for first-line kidney cancer last year. The US FDA approved the combination for this indication in April ... read more

NICE turns down Opdivo/Yervoy combo for kidney cancer

The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for ... to the NHS. The combination was approved in the US earlier this year ... read more

Looking for another news?

Opdivo + Yervoy Approved to Treat MSI-H/dMMR Metastatic Colorectal Cancer

The combination of Opdivo + Yervoy is now approved for ... metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. The approval ... read more

Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial

Bristol-Myers Squibb Company BMY announced that the phase III CheckMate-451 study on immuno-oncology drug Opdivo in combination with Yervoy was unsuccessful ... line non-small-cell lung cancer ("NSCLC ... read more

Bristol-Myers receives European approval for Opdivo plus low dose Yervoy to treat patients with intermediate- and advanced RCC

Bristol-Myers Squibb Company announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab ... is the most common type of kidney cancer in ... read more

FDA approves Opdivo, Yervoy combination for kidney cancer

April 17 (UPI) --The Food and Drug Administration has approved a combination of two immunotherapy drugs, ipilimumab and nivolumab, to treat metastatic kidney cancer. The FDA approved the injection ... read more

FDA OKs Bristol-Myers' Opdivo + Yervoy for first-line kidney cancer

The FDA approves Bristol-Myers Squibb's (BMY-8.4%) combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for the first-line treatment of patients with intermediate- and poor-risk advanced renal ... read more

FDA puts Bristol-Myers' Opdivo-Yervoy combo in fast lane for new kidney cancer nod

Bristol-Myers Squibb could have yet another approval for its Opdivo-plus-Yervoy combo on the way. The FDA has started a priority review on the two-drug combo as a treatment for kidney cancer, based on ... read more

FDA Approves Combo Tx for Intermediate, Poor-Risk Advanced Kidney Cancer

The Food and Drug Administration (FDA) has approved nivolumab (Opdivo; Bristol-Myers Squibb) and ipilimumab (Yervoy; Bristol-Myers Squibb) as combination therapy for ... and metastatic non-small cell ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us